Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Damon A Bell

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Clinical Cardiology|June 17, 2014
Response to familial hypercholesterolemia: an under-recognized but significant concern in cardiology practiceDamon A Bell, Gerald F Watts
Clinical Therapeutics|November 10, 2015
Contemporary and Novel Therapeutic Options for HypertriglyceridemiaDamon A Bell, Gerald F Watts
The Medical Journal of Australia|September 2, 2016
Progress in the care of familial hypercholesterolaemia: 2016Damon A Bell, Gerald F Watts
The Clinical Biochemist. Reviews|December 21, 2019
Revisiting the Biological Variability of Cardiac Troponin: Implications for Clinical PracticeNick S R Lan, Damon A Bell
Australian Health Review : a Publication of the Australian Hospital Association|February 11, 2009
Clinical orientation program for new medical registrars--a qualitative evaluationIan Rosemergy, Damon A Bell, Sisira K Jayathissa
Clinical Genetics|December 14, 2019
Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?Michael M Page, Damon A Bell, Gerald F Watts
Expert Opinion on Pharmacotherapy|September 21, 2024
Olezarsen, a liver-directed <i>APOC3</i> ASO therapy for hypertriglyceridemiaAmanda J Hooper, Damon A Bell, John R Burnett
Expert Opinion on Investigational Drugs|January 8, 2011
Mipomersen, an antisense apolipoprotein B synthesis inhibitorDamon A Bell, Amanda J Hooper, John R Burnett
Emergency Medicine Australasia : EMA|October 9, 2025
Measurement of Serum Ammonia in the ED: Lost OpportunitiesCiselle Meier, Catherine Manolikos, Kharis Burns, et al.
Expert Opinion on Pharmacotherapy|November 30, 2024
Response to the letter to the editor: 'Olezarsen, a liver-directed <i>APOC3</i> ASO therapy for hypertriglyceridemia'Amanda J Hooper, Damon A Bell, John R Burnett
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Clinical Cardiology|June 17, 2014
Response to familial hypercholesterolemia: an under-recognized but significant concern in cardiology practiceDamon A Bell, Gerald F Watts
Clinical Therapeutics|November 10, 2015
Contemporary and Novel Therapeutic Options for HypertriglyceridemiaDamon A Bell, Gerald F Watts
The Medical Journal of Australia|September 2, 2016
Progress in the care of familial hypercholesterolaemia: 2016Damon A Bell, Gerald F Watts
The Clinical Biochemist. Reviews|December 21, 2019
Revisiting the Biological Variability of Cardiac Troponin: Implications for Clinical PracticeNick S R Lan, Damon A Bell
Australian Health Review : a Publication of the Australian Hospital Association|February 11, 2009
Clinical orientation program for new medical registrars--a qualitative evaluationIan Rosemergy, Damon A Bell, Sisira K Jayathissa
Clinical Genetics|December 14, 2019
Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?Michael M Page, Damon A Bell, Gerald F Watts
Expert Opinion on Pharmacotherapy|September 21, 2024
Olezarsen, a liver-directed <i>APOC3</i> ASO therapy for hypertriglyceridemiaAmanda J Hooper, Damon A Bell, John R Burnett
Expert Opinion on Investigational Drugs|January 8, 2011
Mipomersen, an antisense apolipoprotein B synthesis inhibitorDamon A Bell, Amanda J Hooper, John R Burnett
Emergency Medicine Australasia : EMA|October 9, 2025
Measurement of Serum Ammonia in the ED: Lost OpportunitiesCiselle Meier, Catherine Manolikos, Kharis Burns, et al.
Expert Opinion on Pharmacotherapy|November 30, 2024
Response to the letter to the editor: 'Olezarsen, a liver-directed <i>APOC3</i> ASO therapy for hypertriglyceridemia'Amanda J Hooper, Damon A Bell, John R Burnett
Pageof 9